NYSE: NUVBNuvation Bio Inc Stock
$8.03+0.02 (+0.25%)
Updated Nov 28, 2025
NUVB Price
$8.03
Fair Value Price
N/A
Market Cap
$2.75B
52 Week Low
$1.54
52 Week High
$8.24
P/E
-16.39x
P/B
8.45x
P/S
47.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$26.75M
Earnings
-$217.48M
Gross Margin
54.3%
Operating Margin
-786.53%
Profit Margin
-813.1%
Debt to Equity
0.85
Operating Cash Flow
-$190M
Beta
1.36
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NUVB Overview
Panacea Acquisition Corp., a blank check company, focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NUVB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NUVB
Ranked#119 of 485
Ranked#119 of 485
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.88 | A | |
| $340.61 | A | |
| $21.73 | A |
Be the first to know about important NUVB news, forecast changes, insider trades & much more!
NUVB News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NUVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NUVB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NUVB is poor value based on its book value relative to its share price (8.45x), compared to the US Biotechnology industry average (5.35x)
P/B vs Industry Valuation
NUVB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NUVB due diligence checks available for Premium users.
Valuation
NUVB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.39x
Industry
212.11x
Market
45.69x
NUVB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.45x
Industry
5.35x
NUVB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NUVB's financial health
Profit margin
Revenue
$13.1M
Net Income
-$55.8M
Profit Margin
-425.2%
NUVB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NUVB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$601.6M
Liabilities
$275.7M
Debt to equity
0.85
NUVB's short-term assets ($577.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUVB's short-term assets ($577.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUVB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NUVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$52.9M
Investing
-$96.6M
Financing
$501.0k
NUVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NUVB vs Biotech Stocks
Nuvation Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.